Enliven Therapeutics (ELVN) Other Gross PP&E Adjustments (2019 - 2026)
Enliven Therapeutics has reported Other Gross PP&E Adjustments over the past 8 years, most recently at -$1.0 million for Q1 2026.
- Quarterly results put Other Gross PP&E Adjustments at -$1.0 million for Q1 2026, down 2957.58% from a year ago — trailing twelve months through Mar 2026 was -$1.0 million (down 2957.58% YoY), and the annual figure for FY2025 was -$1.4 million, down 319.37%.
- Other Gross PP&E Adjustments reached -$1.0 million in Q1 2026 per ELVN's latest filing, up from -$1.4 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $672000.0 in Q3 2024 and bottomed at -$2.3 million in Q1 2022.
- Median Other Gross PP&E Adjustments over the past 5 years was $372500.0 (2022), compared with a mean of $10750.0.
- The largest annual shift saw Other Gross PP&E Adjustments skyrocketed 596.92% in 2023 before it plummeted 2957.58% in 2026.
- Over 5 years, Other Gross PP&E Adjustments stood at $369000.0 in 2022, then tumbled by 48.24% to $191000.0 in 2023, then skyrocketed by 235.08% to $640000.0 in 2024, then crashed by 319.38% to -$1.4 million in 2025, then rose by 28.13% to -$1.0 million in 2026.
- Business Quant data shows Other Gross PP&E Adjustments for ELVN at -$1.0 million in Q1 2026, -$1.4 million in Q4 2025, and $471000.0 in Q3 2025.